Le Lézard
Classified in: Health
Subject: FDA

The Food and Drug Administration (FDA) grants a « Breakthrough Device Designation » to the MIScolitm, an innovative vertebral body tethering device to treat idiopathic scoliosis

MONTREAL, June 18, 2021  /CNW Telbec/ - Spinologics Inc. /  Spino Modulation Inc., a subsidiary of Spinologics Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted the company a Breakthrough Device Designation for its MIScolitm system, an innovative vertebral body tethering (VBT) device to treat scoliosis in young adolescents.

The FDA Breakthrough Device Program is intended to help patients receive more timely access to certain medical devices that have the potential to provide more effective treatment for life-threatening or irreversibly debilitating diseases or conditions, including a prioritized review of market approval regulatory submissions.

The MIScolitm system is one of a few VBT devices that are under investigation, or limited market release, in many countries. Various medical device developers have committed to developing VBT solutions to serve an unmet need in the scoliosis surgical treatment market.

VBT is a promising and lesser invasive alternative to spine fusion, today's standard of care when adolescents need a surgical intervention to correct a curvature of the spine. Patients, and their parents, are looking for treatment options that are less traumatic than fusion, which is associated with long in hospital and at-home recovery times, growth and mobility restrictions, longer term pain and narcotics requirements and significant surgical scars.

Adolescent Idiopathic Scoliosis (AIS) is a common and under diagnosed condition amongst adolescents across the world. It is estimated that 2-3% of the population possess some degree of AIS. If detected, physical rehabilitation and braces are used to delay the progression of spine curvature. In the more severe cases, surgical intervention is needed. Spine fusion is mostly recommended once the patient has finished growing, therefore teenagers must live with a worsening condition until early adulthood. VBT has the potential to disrupt treatment paradigms as it can be performed earlier in the patient's history. A key mechanism to the success of this therapy is by leveraging the patient's growing spine, known as growth modulation.

Spinologics was founded in 2010 by three Orthopedics spine surgeons from Montreal (Canada) to create an environment where they develop surgical tools for back surgery.

Spino-Modulation focuses on the development of the MIScolitm system, including sponsoring a pivotal clinical trial in Canada.

SOURCE Spinologics

These press releases may also interest you

at 07:05
Taysha Gene Therapies, Inc. , a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large...

at 07:05
Kiromic BioPharma, Inc. ("Kiromic" or the "Company"), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) platform to discover and develop cell and gene therapies with a therapeutic...

at 07:05
Concert Pharmaceuticals, Inc. today announced that it has completed patient enrollment in THRIVE-AA1, the first Phase 3 clinical trial to evaluate the efficacy and safety of CTP?543, an oral Janus kinase (JAK) inhibitor, in adult patients with...

at 07:05
OncoNano Medicine, Inc. today announced that the Cancer Prevention and Research Institute of Texas (CPRIT) will convert $18.4 million in grant award funding into an equity investment in OncoNano. Proceeds of the financing will be used to support...

at 07:05
Castle Biosciences, Inc. , a company applying innovative diagnostics to inform disease management decisions and improve patient outcomes, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30,...

at 07:05
Viking Therapeutics, Inc. (Viking) , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that preclinical data from a series of novel dual agonists of the...

News published on 18 june 2021 at 09:00 and distributed by: